SSR3 and breast carcinoma: Dmello et al. (2022) found that the endoplasmic reticulum protein SSR3 (signal sequence receptor subunit 3) was associated with paclitaxel resistance in breast cancer, and that knockdown of SSR3 made cells resistant to PTX, while overexpression made them sensitive to PTX.